Compare AbbVie Inc (ABBV) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Lululemon Athletica Inc — how do they compare? AbbVie Inc trades at $248.77 (market cap $441.94B), while Lululemon Athletica Inc trades at $121.4 (market cap $14.26B). The key difference: AbbVie Inc is far larger — about 31× Lululemon Athletica Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| ABBV | LULU | |
|---|---|---|
Market Cap | $441.94B | $14.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $215.88 |
52-Week Low | $197.38 | $105.43 |
Enterprise Value | $506.19B | $14.89B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with $61.16B revenue in 2025 and consistent earnings beats, though net margins have compressed from 20.4% in 2022 to 6.9%. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional accumulation signal confidence. Technical indicators show support at $248 and resistance at $251, with the stock trading near analyst consensus targets.
Outlook remains positive with 70.7% analyst buy ratings and $278.69 price target, representing 11.5% upside. Key opportunities include immunology growth from Skyrizi/Rinvoq and pipeline advancements. Risks include patent cliffs in the 2030s, debt levels at 50.4% of assets, and margin pressure from competitive and pricing headwinds. The dividend yield and earnings recovery in 2026 forecast support the bullish case.
Lululemon stock trades at $120.88, down 5.41% amid broader market weakness in the premium apparel sector. The company maintains strong fundamentals with a P/E of 10.17, net income margin of 13.03%, and consistent earnings beats. Technical indicators show a bullish moving average trend despite overbought RSI readings, with key resistance near $129.
Investment outlook remains positive given undervaluation metrics and international growth potential, though risks include U.S. demand softness and competitive pressures. Analyst consensus targets $129.29 with 41% buy ratings, suggesting moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
